Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2018 to Q4 2025

Type / Class
Equity / Class A Common Stock, par value $0.01
Symbol
AMRX on Nasdaq
Shares outstanding
315,976,000
Price per share
$12.60
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
150,648,996
Total reported value
$1,508,361,145
% of total 13F portfolios
0%
Share change
+7,749,626
Value change
+$80,964,127
Number of holders
244
Price from insider filings
$12.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Patel Tushar Bhikhubhai 16% $407,085,391 48,578,209 Patel Tushar Bhikhubhai 14 Mar 2025
Patel Chintu 8.2% $259,359,420 25,910,032 Patel Chintu 03 Oct 2025
Patel Dipan 7.6% -1.2% $238,528,210 23,828,992 0% Patel Dipan 03 Oct 2025
Patel Chirag K. 7.1% $176,777,955 22,180,421 Patel Chirag K. 06 Aug 2025
Mahesh Akram 6.6% $172,282,400 20,558,759 Akram Mahesh 31 Mar 2025
VANGUARD GROUP INC 5% $132,091,652 15,762,727 The Vanguard Group 31 Mar 2025

As of 30 Sep 2025, 244 institutional investors reported holding 150,648,996 shares of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX). This represents 48% of the company’s total 315,976,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) together control 37% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 5.7% 17,954,973 +2.3% 0% $179,729,279
BlackRock, Inc. 4.5% 14,073,653 +16% 0% $140,877,267
Rubric Capital Management LP 3.9% 12,334,941 +5.3% 1.7% $123,472,759
TPG GP A, LLC 3.9% 12,328,767 0% 6.7% $123,410,958
CITADEL ADVISORS LLC 1.8% 5,729,299 +1.9% 0.05% $57,350,283
DIMENSIONAL FUND ADVISORS LP 1.7% 5,431,134 +2.5% 0.01% $54,360,826
Nantahala Capital Management, LLC 1.3% 4,224,564 -3.3% 2.6% $42,287,886
GEODE CAPITAL MANAGEMENT, LLC 1.3% 4,034,633 +7.3% 0% $40,393,130
STATE STREET CORP 1.3% 3,973,748 +1.5% 0% $39,777,217
NEUBERGER BERMAN GROUP LLC 1.2% 3,716,075 -0.19% 0.03% $37,176,822
MORGAN STANLEY 1.1% 3,503,081 +40% 0% $35,065,847
MILLENNIUM MANAGEMENT LLC 1.1% 3,332,751 -34% 0.03% $33,360,838
Nuveen, LLC 1% 3,225,232 +21% 0.01% $32,284,572
ACADIAN ASSET MANAGEMENT LLC 0.82% 2,590,522 -2.7% 0.05% $25,913,000
GOLDMAN SACHS GROUP INC 0.78% 2,460,214 +10% 0% $24,626,742
BlackBarn Capital Partners LP 0.69% 2,189,452 -36% 7.2% $21,916,415
Assenagon Asset Management S.A. 0.68% 2,150,041 +187% 0.03% $21,521,910
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.66% 2,082,814 +14% 0% $20,848,968
Qube Research & Technologies Ltd 0.56% 1,757,653 -8% 0.02% $17,594,107
Invesco Ltd. 0.53% 1,685,386 +44% 0% $16,870,714
NORTHERN TRUST CORP 0.52% 1,628,272 +1.1% 0% $16,299,002
D. E. Shaw & Co., Inc. 0.5% 1,565,211 +69% 0.01% $15,667,762
ROYAL BANK OF CANADA 0.49% 1,538,938 +0.02% 0% $15,405,000
AMERIPRISE FINANCIAL INC 0.47% 1,471,636 -14% 0% $14,731,076
UBS Group AG 0.46% 1,445,801 -8.7% 0% $14,472,468

Institutional Holders of Amneal Pharmaceuticals, Inc. - Class A Common Stock, par value $0.01 (AMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 4,764,148 $60,051,079 +$32,338,901 $12.60 11
2025 Q3 150,648,996 $1,508,361,145 +$80,964,127 $10.01 244
2025 Q2 141,656,835 $1,146,033,099 +$54,531,165 $8.09 237
2025 Q1 134,446,153 $1,126,693,374 +$84,513,716 $8.38 231
2024 Q4 125,924,745 $997,304,941 -$136,419,334 $7.92 194
2024 Q3 142,604,810 $1,186,537,769 +$32,197,946 $8.32 180
2024 Q2 138,650,532 $880,442,706 +$192,209,856 $6.35 180
2024 Q1 108,100,412 $655,086,652 -$9,856,313 $6.06 173
2023 Q4 3,856,052 $23,416,321 -$574,329 $6.07 3
2023 Q3 101,896,343 $430,042,740 +$19,687,726 $4.22 141
2023 Q2 97,368,876 $301,754,108 +$4,217,184 $3.10 121
2023 Q1 96,404,763 $133,992,130 -$8,234,383 $1.39 139
2022 Q4 101,827,015 $202,640,136 +$4,431,021 $1.99 153
2022 Q3 91,936,831 $185,729,628 -$770,772 $2.02 139
2022 Q2 97,853,345 $311,192,849 -$2,007,306 $3.18 137
2022 Q1 92,598,580 $385,758,539 -$3,150,382 $4.17 151
2021 Q4 100,273,941 $478,793,810 -$1,213,873 $4.79 145
2021 Q3 100,314,917 $534,951,080 +$2,644,924 $5.34 150
2021 Q2 99,530,970 $509,505,477 -$13,562,876 $5.12 153
2021 Q1 101,561,492 $683,396,934 +$22,659,150 $6.73 154
2020 Q4 92,046,870 $420,590,386 -$4,897,752 $4.57 126
2020 Q3 93,114,553 $361,255,017 +$3,086,054 $3.88 129
2020 Q2 101,620,932 $483,700,077 +$13,664,961 $4.76 128
2020 Q1 98,243,413 $341,841,040 -$17,274,653 $3.48 114
2019 Q4 101,102,133 $487,286,241 -$9,238,952 $4.82 113
2019 Q3 108,233,131 $313,902,694 +$26,260,745 $2.90 108
2019 Q2 95,251,857 $682,942,286 -$98,037,351 $7.17 113
2019 Q1 101,633,429 $1,440,119,537 -$98,585,986 $14.17 143
2018 Q4 116,115,404 $1,571,109,084 +$90,619,744 $13.53 154
2018 Q3 107,940,783 $2,395,235,089 +$286,780,327 $22.19 159
2018 Q2 97,367,847 $1,597,817,365 +$1,597,526,989 $16.41 159